Showing 2791-2800 of 8921 results for "".
Journal Club: Atopic Dermatitis Control Tool
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-atopic-dermatitis-control-tool/26734/Peter Lio, MD, talks with Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist practicing in Boise, Idaho, about the Atopic Dermatitis Control Tool (ADCT). Highlighted in a recent study published in the British Journal of Dermatology, the ADCT has been said to provide patienDermWireTV: Qwo Approved, Assessing Resident Anxiety
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-qwo-approved-assessing-resident-anxiety/19830/FDA has approved Qwo (collagenase clostridium histolyticum-aaes) from Endo, the first injectable treatment approved for moderate to severe cellulite in the buttocks of adult women. A recent survey offers perspective on anxiety among third-year dermatology residents in light of the COVID crisis. AlleTreating Non-melanoma Skin Cancer: What’s New and Exciting
https://practicaldermatology.com/conferences/scale-2023/treating-non-melanoma-skin-cancer-whats-new-and-exciting/20201/Dermatologists have a host of new tools for treating advanced basal and squamous cell carcinomas. Todd Schlesinger, MD, discusses hedgehog pathway inhibitors and immunotherapy and their growing role in treating non-melanoma skin cancers.Warts and All: Treating and Assessing Warts During COVID-19
https://practicaldermatology.com/series/dermatology-dispatches/warts-and-all-treating-and-assessing-warts-during-covid-19/19774/Many warts can be safely treated at home during the COVID-19 pandemic, but new onset warts that are changing colors or bleeding could be squamous cell carcinomas and may require evaluation, explains Neal Bhatia, MD.First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingScientifically Speaking: Nanopulse Stimulation with Darrin Uecker
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-nanopulse-stimulation-with-darrin-uecker/20111/The CellFX system from Pulse Biosciences is a true platform technology, says President/CEO Darrin Uecker. He talks to host Joel L. Cohen, MD about the technology, its application, and potential future uses.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workScientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta Medica